EUDA Health Holdings Limited (EUDA)
NASDAQ: EUDA · Real-Time Price · USD
13.21
-0.99 (-6.97%)
At close: Aug 21, 2026, 4:00 PM EDT
13.20
-0.01 (-0.08%)
After-hours: Aug 21, 2026, 4:10 PM EDT
EUDA Health Holdings Revenue
In the year 2025, EUDA Health Holdings had annual revenue of $6.82M with 70.04% growth. EUDA Health Holdings had revenue of $3.76M in the half year ending December 31, 2025.
Revenue (ttm)
$6.82M
Revenue Growth
+70.04%
P/S Ratio
5.80
Revenue / Employee
$55,449
Employees
123
Market Cap
39.56M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.82M | 2.81M | 70.04% |
| Dec 31, 2024 | 4.01M | 304.55K | 8.22% |
| Dec 31, 2023 | 3.71M | -57.84K | -1.54% |
| Dec 31, 2022 | 3.76M | -794.23K | -17.42% |
| Dec 31, 2021 | 4.56M | -4.32M | -48.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fathom Holdings | 406.93M |
| Offerpad Solutions | 404.53M |
| Altisource Portfolio Solutions | 182.50M |
| Star Holdings | 98.27M |
| Fangdd Network Group | 50.73M |
| American Strategic Investment Co. | 33.41M |
| J.W. Mays | 21.43M |
| Linkhome Holdings | 20.80M |
EUDA News
- 23 days ago - EUDA Health Announces Collaboration to Advance an Integrated iPSC Cell Therapy Program for Oncology and Wellness • Targets global distribution for innovative Oncology products - GlobeNewsWire
- 25 days ago - EUDA Health Signs Important Tri-Party Memorandum of Understanding with GO POSB Organoids and Shenzhen Inno to Significantly Advance Next-Generation iPSC and NK-TCR Cell Therapies - GlobeNewsWire
- 2 months ago - EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask - GlobeNewsWire
- 2 months ago - EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency - GlobeNewsWire
- 4 months ago - EUDA Highlights Shenzhen Inno's Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development - GlobeNewsWire
- 5 months ago - EUDA Announces Reverse Stock Split of its Ordinary Shares - GlobeNewsWire
- 6 months ago - EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant - GlobeNewsWire
- 7 months ago - EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform - GlobeNewsWire